Flex Pharma Reports Year End 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Flex Pharm (FLKS) PT Raised to $27 at Cantor Fitzgerald Ahead of Consumer Product Launch
March 18, 2015 7:23 AM EDTCantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and raised her price target on Flex Pharma (NASDAQ: FLKS) to $27.00 (from $22.00) following Q4 results.
The price target hike reflect the pre-launch for the consumer product for exercise associated muscle cramps... More
